Comparison of the Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Ratio Combination to Insulin Glargine in Patients With Type 2 Diabetes Insufficiently Controlled on Basal Insulin (Lixilan-L-CN)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03798080 |
|
Recruitment Status :
Completed
First Posted : January 9, 2019
Last Update Posted : January 13, 2021
|
Sponsor:
Sanofi
Information provided by (Responsible Party):
Sanofi
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
Primary Objective:
To demonstrate the superiority of iGlarLixi (fixed ratio combination of insulin glargine and lixisenatide) to insulin glargine on glycemic control as assessed by glycated hemoglobin A1c (HbA1c) change in patients with type 2 diabetes mellitus (T2DM) who are not sufficiently controlled with basal insulin.
Secondary Objectives:
- To assess the effects of iGlarLixi in comparison with insulin glargine
- To assess the safety in each treatment group
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Type 2 Diabetes Mellitus | Drug: Insulin glargine/Lixisenatide (HOE901/AVE0010) Drug: Insulin glargine (HOE901) Drug: Metformin | Phase 3 |
The maximum study duration per patient will be approximately 33 weeks: an up to 2-week screening period (it can be exceptionally extended up to one additional week), a 30-week, open label randomized treatment period comparing iGlarLixi to insulin glargine (± metformin for both treatments), and a 3-day post-treatment safety follow-up period.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 426 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | A Randomized, 30-week, Active-controlled, Open-label, 2 Treatment-arm, Parallel Group, Multicenter Study Comparing Efficacy and Safety of iGlarLixi to Insulin Glargine With or Without Metformin in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled on Basal Insulin With or Without Oral Antidiabetic Drug(s) |
| Actual Study Start Date : | February 19, 2019 |
| Actual Primary Completion Date : | December 1, 2020 |
| Actual Study Completion Date : | December 1, 2020 |
Resource links provided by the National Library of Medicine
MedlinePlus Genetics related topics:
Type 2 diabetes
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Soliqua (insulin glargine/lixisenatide)
iGlarLixi (insulin glargine/lixisenatide) will be self-administered subcutaneously once daily in the morning with or without metformin for 30 weeks
|
Drug: Insulin glargine/Lixisenatide (HOE901/AVE0010)
Pharmaceutical form: solution Route of administration: subcutaneous Other Names:
Drug: Metformin Pharmaceutical form: tablet Route of administration: oral |
|
Active Comparator: Lantus (insulin glargine)
Insulin glargine will be self-administered subcutaneously once daily at any time of the day with or without metformin for 30 weeks
|
Drug: Insulin glargine (HOE901)
Pharmaceutical form: solution Route of administration: subcutaneous Other Name: Lantus Drug: Metformin Pharmaceutical form: tablet Route of administration: oral |
Primary Outcome Measures :
- Change in HbA1c [ Time Frame: From Baseline to Week 30 ]Change in glycated hemoglobin (HbA1c) from baseline to Week 30
Secondary Outcome Measures :
- Patients with HbA1c <7.0% [ Time Frame: At Week 30 ]Percentage of patients reaching HbA1c <7% at Week 30
- Patients with HbA1c ≤ 6.5% [ Time Frame: At Week 30 ]Percentage of patients reaching HbA1c ≤ 6.5% at Week 30
- Change in postprandial plasma glucose (PPG) [ Time Frame: From Baseline to Week 30 ]Absolute change in 2-hour blood glucose excursion and PPG during meal test from baseline to Week 30
- Change in self-monitored plasma glucose (SMPG) profile [ Time Frame: From Baseline to Week 30 ]Absolute change in 7-point SMPG profiles from baseline to Week 30 (each time point and average daily value)
- Patients with HbA1c <7.0% with no body weight gain [ Time Frame: At Week 30 ]Percentage of patients reaching HbA1c <7% with no body weight gain at Week 30
- Change in body weight [ Time Frame: From Baseline to Week 30 ]Absolute change in body weight from baseline to Week 30
- Patients with HbA1c <7.0% with no body weight gain and no documented symptomatic hypoglycemia [ Time Frame: At Week 30 ]Percentage of patients reaching HbA1c <7% with no body weight gain at Week 30 and no documented (plasma glucose [PG] ≤70 mg/dL [3.9mmol/L]) symptomatic hypoglycemia during the 30-week randomized treatment period
- Patients requiring rescue therapy [ Time Frame: From Baseline to Week 30 ]Percentage of patients requiring rescue therapy during the 30-week randomized treatment period
- Change in fasting plasma glucose (FPG) [ Time Frame: From Baseline to Week 30 ]Absolute change in FPG from baseline to Week 30
- Confirmed hypoglycemia [ Time Frame: From Baseline to Week 30 ]Severe hypoglycemia and episodes of hypoglycemia documented with PG ≤ 70 mg/dL (3.9mmol/L) regardless of symptoms
- Adverse events (AEs) [ Time Frame: From Baseline to Week 30 ]Number of AEs, Serious AEs, AEs of Special Interest, and AEs requiring specific monitoring from baseline to Week 30
- Immunogenicity (antibody variables) [ Time Frame: From Baseline to Week 30 ]Anti-lixisenatide antibodies (in iGlarLixi group) and anti-insulin antibodies from baseline to Week 30
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion criteria :
- Patients with type 2 diabetes mellitus (T2DM) diagnosed for at least 1 year and treated with basal insulin for at least 6 months before screening visit (V1).
- Patients who have been treated with a stable basal insulin regimen (ie, type of insulin and time/frequency of the injection), for at least 3 months before screening visit (V1).
- Stable total daily basal insulin dose (±20 %) in the range of 10 and 25 U/day for at least 2 months before screening visit (V1). Total daily dose should be within the range of 10-25 U, both inclusive, on the day of screening, but individual fluctuations of ±20% within 2 months prior to screening are acceptable.
- For patients receiving basal insulin AND 1 or 2 oral anti-diabetic drugs (OADs): the OAD dose(s) must be stable during the 3 months prior to screening. The OAD(s) can be 1 to 2 out of:
- Metformin (≥1500 mg/day or maximal tolerated dose).
- Sulfonylurea (SU)/glinide.
- Alpha-glucosidase inhibitor (alpha-GI).
- Sodium-glucose co-transporter 2 (SGLT2) inhibitor.
- Dipeptidyl-peptidase-4 (DPP-4) inhibitor.
- Fasting plasma glucose (FPG) ≤160 mg/dL (8.9 mmol/L) at screening visit (V1) (can be repeated once to confirm).
- Signed written informed consent.
Exclusion criteria:
- Age <18 years at screening visit (V1).
- Screening glycated hemoglobin A1c(HbA1c) <7.0% or >10.5%.
- History of hypoglycemia unawareness.
- History of metabolic acidosis, including diabetic ketoacidosis within one year prior to screening.
- Use of oral or injectable glucose-lowering agents other than those stated in the inclusion criteria within 3 months prior to screening.
- Previous use of insulin regimen other than basal insulin, eg, prandial or pre-mixed insulin, within one year prior to screening (Note: Short term treatment [≤10 days] due to intercurrent illness is allowed).
- History of discontinuation of a previous treatment with glucagon-like-peptide-1 receptor agonists (GLP-1 RAs) due to safety/tolerability reason or lack of efficacy.
- Use of systemic glucocorticoids (excluding topical application or inhaled forms) for 1 week or more within 3 months prior to screening.
- Use of weight loss drugs within 3 months prior to screening.
- Use of any investigational drug within 1 month or 5 half-lives, whichever is longer, prior to screening.
- Within 6 months prior to screening: history of myocardial infarction, stroke, or heart failure requiring hospitalization.
- Planned coronary, carotid, or peripheral revascularization procedures to be performed during the study period.
- Known history of drug or alcohol abuse within 6 months prior to screening.
- Uncontrolled or inadequately controlled hypertension at the time of screening with a resting systolic blood pressure >180 mmHg or diastolic blood pressure >95 mmHg.
- Laboratory findings at screening visit:
- Amylase and/or lipase >3 times the upper limit of normal (ULN) laboratory range.
- Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >3 ULN.
- Total bilirubin >1.5 ULN (except in case of Gilbert's syndrome).
- Calcitonin ≥20 pg/mL (5.9 pmol/L).
- Hemoglobin <10.5 g/dL and/or neutrophils <1500/mm3 and/or platelets <100 000/mm3.
- Positive test for hepatitis B surface antigen (HBsAg) and/or hepatitis C antibody (HCAb).
- Positive urine pregnancy test in female of childbearing potential.
- For patient not treated with metformin at screening: severe renal function impairment with an estimated glomerular filtration rate (eGFR) <30 mL/min/1.73m2 or end-stage renal disease.
- Clinically relevant history of gastrointestinal disease associated with prolonged nausea and vomiting, including (but not limited to): gastroparesis, unstable (ie, worsening) or not controlled (ie, prolonged nausea and vomiting) gastroesophageal reflux disease requiring medical treatment, within 6 months prior to the time of screening visit; or history of surgery affecting gastric emptying.
- History of pancreatitis (unless pancreatitis was related to gallstones and cholecystectomy has been performed), pancreatitis during previous treatment with incretin therapies, chronic pancreatitis, pancreatectomy.
- Personal or immediate family history of medullary thyroid cancer (MTC) or genetic conditions that predispose to MTC (eg, multiple endocrine neoplasia syndromes).
- Mean fasting self-monitored plasma glucose (SMPG) is >160 mg/dL (8.9 mmol/L), calculated from all available (minimum of 4 self-measurements) values during the 7 days prior to randomization.
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03798080
Locations
Show 45 study locations
Sponsors and Collaborators
Sanofi
Investigators
| Study Director: | Clinical Sciences & Operations | Sanofi |
| Responsible Party: | Sanofi |
| ClinicalTrials.gov Identifier: | NCT03798080 |
| Other Study ID Numbers: |
EFC14944 U1111-1190-7781 ( Other Identifier: UTN ) |
| First Posted: | January 9, 2019 Key Record Dates |
| Last Update Posted: | January 13, 2021 |
| Last Verified: | January 2021 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Yes |
| Plan Description: | Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/ |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
| Product Manufactured in and Exported from the U.S.: | No |
Additional relevant MeSH terms:
|
Diabetes Mellitus Diabetes Mellitus, Type 2 Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases Insulin |
Insulin, Globin Zinc Metformin Insulin Glargine Lixisenatide Hypoglycemic Agents Physiological Effects of Drugs |